Cardiovascular Drugs Practice Questions

Q: Dopamine given in acute CHF does NOT act on which of the following receptors?

Alpha 1 receptors. **Explanation:** The pharmacological action of Dopamine is uniquely **dose-dependent**. To understand why Alpha-1 receptors are the correct answer in the context of acute Congestive Heart Failure (CHF), we must look at the therapeutic goals and dose ranges: 1. **Low Dose (0.5–2 µg/kg/min):** Acts primarily on **D1 receptors** (Option B) located in the renal, mesenteric, and coronary beds. This causes vasodilation and increases renal blood flow (Option A), promoting diuresis. 2. **Intermediate Dose (2–10 µg/kg/min):** Acts primarily on **Beta-1 receptors** (Option C). This increases myocardial contractility (positive inotropy) and cardiac output, which is the primary therapeutic goal in acute CHF. 3. **High Dose (>10 µg/kg/min):** Acts on **Alpha-1 receptors** (Option D), causing systemic vasoconstriction. **Why Alpha-1 is the correct answer:** In the management of acute CHF, the goal is to improve cardiac output and reduce afterload. Activating Alpha-1 receptors causes peripheral vasoconstriction, which increases afterload and myocardial oxygen demand, potentially worsening heart failure. Therefore, Dopamine is titrated to "inotropic doses" (Beta-1) and not "pressor doses" (Alpha-1) in this specific clinical setting. **Clinical Pearls for NEET-PG:** * **Dopamine vs. Dobutamine:** Dobutamine is often preferred in CHF because it has more prominent Beta-1 effects and lacks the Alpha-1 mediated vasoconstriction seen with high-dose Dopamine. * **Fenoldopam:** A selective D1 agonist used in hypertensive emergencies to maintain renal perfusion. * **Renal Dose Myth:** Recent evidence suggests the "renal dose" of dopamine does not significantly improve outcomes in acute renal failure, though it remains a high-yield exam concept.

Q: Which of the following drugs is NOT used in the management of pulmonary hypertension?

Alpha blocker. ### Explanation The management of Pulmonary Arterial Hypertension (PAH) focuses on reducing pulmonary vascular resistance through specific pathways: the **Nitric Oxide pathway**, the **Endothelin pathway**, and the **Prostacyclin pathway**. **Why Alpha Blockers are NOT used:** Alpha-blockers (like Prazosin) act primarily on peripheral $\alpha_1$ receptors to cause systemic vasodilation. They do not have a selective or significant effect on the pulmonary vasculature. Using them in PAH can lead to systemic hypotension without effectively lowering pulmonary artery pressure, potentially worsening the patient's hemodynamic status. **Analysis of Other Options:** * **Calcium Channel Blockers (CCBs):** High-dose CCBs (e.g., Nifedipine, Diltiazem, Amlodipine) are the first-line treatment for a small subset of patients who show a positive response during **Vasoreactivity Testing** (usually with inhaled Nitric Oxide). * **Endothelin Receptor Antagonists (ERAs):** Drugs like **Bosentan** (non-selective), **Ambrisentan**, and **Macitentan** (selective $ET_A$) block the potent vasoconstrictor effects of endothelin-1, which is elevated in PAH. * **Prostacyclins:** PAH is characterized by a deficiency of prostacyclin ($PGI_2$). Synthetic analogs like **Epoprostenol** (IV), **Treprostinil**, and **Iloprost** act as potent pulmonary vasodilators and inhibitors of platelet aggregation. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** For PAH, the specific choice depends on the functional class, but **Sildenafil** (PDE-5 inhibitor) is frequently used. * **Bosentan Side Effect:** It is known for **hepatotoxicity** (requires monthly LFTs) and is highly **teratogenic**. * **Riociguat:** A Soluble Guanylate Cyclase (sGC) stimulator used in PAH and chronic thromboembolic pulmonary hypertension (CTEPH). * **Selexipag:** An oral selective $IP$ prostacyclin receptor agonist.

Q: All of the following antihypertensive drugs increase plasma renin activity except?

Clonidine. **Explanation:** The regulation of **Plasma Renin Activity (PRA)** is primarily governed by the sympathetic nervous system (via $\beta_1$ receptors on juxtaglomerular cells), renal baroreceptors, and feedback loops involving Angiotensin II. **1. Why Clonidine is the correct answer:** Clonidine is a **centrally acting $\alpha_2$ agonist**. It stimulates $\alpha_2$ receptors in the nucleus tractus solitarius, leading to a decrease in sympathetic outflow from the brain. This reduction in sympathetic tone results in **decreased stimulation of $\beta_1$ receptors** in the kidney, thereby **inhibiting renin release**. Consequently, Clonidine (along with Methyldopa) decreases PRA. **2. Why the other options are incorrect:** * **Hydralazine (Vasodilator):** Causes significant peripheral vasodilation, leading to a drop in blood pressure. This triggers a potent **reflex sympathetic activation**, which stimulates $\beta_1$ receptors to increase renin release. * **Nifedipine (Calcium Channel Blocker):** Similar to other dihydropyridines, it causes vasodilation and a subsequent **reflex increase in sympathetic activity**, which raises PRA. * **Captopril (ACE Inhibitor):** By blocking the conversion of Angiotensin I to Angiotensin II, it removes the **negative feedback** that Angiotensin II normally exerts on renin release. This leads to a compensatory (reactive) increase in PRA. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs that Decrease PRA:** $\beta$-blockers (e.g., Propranolol), Centrally acting drugs (Clonidine, Methyldopa), and Direct Renin Inhibitors (Aliskiren—though Aliskiren decreases *activity*, it actually increases renin *concentration*). * **Drugs that Increase PRA:** Diuretics, ACE inhibitors, ARBs, CCBs, and direct vasodilators. * **Clonidine Withdrawal:** Abrupt cessation can lead to a **rebound hypertensive crisis** due to a sudden surge in catecholamines.

Q: All of the following drugs are used in the management of acute myocardial infarction except?

Calcium channel blockers. Explanation: The management of Acute Myocardial Infarction (AMI) focuses on restoring coronary blood flow and reducing myocardial oxygen demand. Calcium Channel Blockers (CCBs), specifically short-acting dihydropyridines like Nifedipine, are generally avoided in the acute phase of MI. They can cause reflex tachycardia and peripheral vasodilation, which may worsen myocardial ischemia and increase mortality. While non-dihydropyridines (Verapamil/Diltiazem) may be used in specific cases (e.g., persistent ischemia where beta-blockers are contraindicated), they are not standard first-line therapy.Analysis of Incorrect Options: * Tissue Plasminogen Activator (tPA): A thrombolytic agent (e.g., Alteplase) used in STEMI to dissolve the occluding thrombus and achieve reperfusion when primary PCI is not immediately available [1]. * Intravenous Beta Blockers: These reduce heart rate, contractility, and blood pressure, thereby decreasing myocardial oxygen demand. They help limit infarct size and reduce the risk of ventricular arrhythmias. * Acetylsalicylic Acid (Aspirin): A cornerstone of treatment. It inhibits platelet aggregation by irreversibly inhibiting COX-1, preventing further thrombus propagation [2]. Clinical Pearls for NEET-PG: * MONA regimen: Standard initial care includes Morphine, Oxygen (if hypoxic), Nitrates, and Aspirin. * Beta-blockers are contraindicated in MI if the patient has signs of heart failure, low output state, or risk of cardiogenic shock. * Nifedipine (short-acting) is specifically contraindicated in AMI due to the risk of "coronary steal" and reflex tachycardia. * ACE Inhibitors should be started within 24 hours to prevent ventricular remodeling.

Q: All of the following are true regarding rabeprazole except:

It causes hypotension.. **Explanation:** The question contains a slight typographical error in the drug name; it refers to **Ranolazine**, a novel anti-anginal agent (Rabeprazole is a Proton Pump Inhibitor). **1. Why Option A is the Correct Answer (The "Except"):** Ranolazine is unique because it provides anti-anginal efficacy **without significantly affecting heart rate or blood pressure.** Unlike nitrates, beta-blockers, or calcium channel blockers, ranolazine does not cause hypotension. Therefore, the statement "It causes hypotension" is false. **2. Analysis of Other Options:** * **Option B:** Ranolazine is approved as a **first-line treatment** for chronic stable angina (often used when other drugs are contraindicated or as add-on therapy). * **Option C:** A significant high-yield property of Ranolazine is its ability to **reduce HbA1c levels**, thereby improving glycemic control in diabetic patients with angina. * **Option D:** Ranolazine has a slow onset of action and works by inhibiting the **late inward sodium current ($I_{Na}$)** in the myocardium. This prevents calcium overload but does not provide immediate vasodilation; hence, it is **not indicated for acute attacks.** **3. NEET-PG High-Yield Pearls:** * **Mechanism of Action:** Inhibits late $I_{Na}$ current $\rightarrow$ decreases intracellular $Ca^{2+}$ $\rightarrow$ improves myocardial relaxation and reduces wall tension. * **ECG Change:** It can cause **QT interval prolongation** (though it rarely leads to Torsades de Pointes). * **Metabolism:** It is metabolized by **CYP3A4**; therefore, inhibitors like ketoconazole or clarithromycin are contraindicated. * **Clinical Advantage:** Ideal for patients who have low baseline blood pressure or heart rate where traditional anti-anginals cannot be up-titrated.

Q: All of the following ACE inhibitors are prodrugs and are activated by esterases in the liver except?

Captopril. **Explanation:** Most Angiotensin-Converting Enzyme (ACE) inhibitors are formulated as **prodrugs** to improve their oral bioavailability. These drugs are inactive in their original form and must undergo hydrolysis by **hepatic esterases** to be converted into their active "–at" metabolites (e.g., Enalapril to Enalaprilat). **Why Captopril is the Correct Answer:** **Captopril** and **Lisinopril** are the two primary exceptions to this rule. They are **not prodrugs**; they are active molecules upon ingestion and do not require hepatic metabolism for activation. This makes them particularly useful in patients with severe liver dysfunction, as their therapeutic effect is not dependent on hepatic esterase activity. **Analysis of Incorrect Options:** * **Ramipril:** A common prodrug converted to its active form, *Ramiprilat*. It is highly lipophilic and widely used for its cardioprotective benefits. * **Perindopril:** A long-acting prodrug converted to *Perindoprilat*. It is frequently used in the management of stable coronary artery disease. * **Spirapril:** A prodrug converted to *Spiraprilat*. It is unique because it is eliminated equally by both renal and biliary routes, making it safer in patients with renal impairment. **High-Yield NEET-PG Pearls:** 1. **The "Pril" Rule:** All ACE inhibitors are prodrugs **EXCEPT Captopril and Lisinopril.** 2. **Excretion:** Most ACE inhibitors are excreted renally. **Fosinopril** and **Spirapril** are notable for having significant compensatory biliary excretion, making them safer in renal failure. 3. **Lisinopril** is the only ACE inhibitor that is not highly protein-bound and is excreted unchanged in the urine. 4. **Side Effects:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased Potassium, Leukopenia).

Q: In congestive cardiac failure, which of the following is NOT used?

Trimetazidine. **Explanation:** The management of Congestive Cardiac Failure (CCF) focuses on reducing preload, afterload, and inhibiting maladaptive neurohumoral remodeling. **Why Trimetazidine is the correct answer:** Trimetazidine is a **pFOX (partial fatty acid oxidation) inhibitor**. It shifts myocardial metabolism from fatty acid oxidation to glucose oxidation, which requires less oxygen to produce ATP. While it is an effective anti-anginal agent used in stable coronary artery disease, it is **not** a standard treatment for the acute or chronic management of cardiac failure itself. It does not provide the hemodynamic benefits (like diuresis or vasodilation) required in CCF. **Analysis of Incorrect Options:** * **Spironolactone:** An aldosterone antagonist (MRA) that is a cornerstone in CCF management (NYHA Class II-IV). It prevents myocardial fibrosis and reduces mortality. * **Nitrates:** These are venodilators that reduce **preload**. They are particularly useful in acute heart failure and in combination with Hydralazine (especially in African American populations) to reduce mortality. * **Nesiritide:** A recombinant **B-type Natriuretic Peptide (BNP)**. It causes vasodilation and natriuresis, used primarily in the management of acutely decompensated heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs reducing mortality in CCF:** ACE inhibitors/ARBs, Beta-blockers (Carvedilol, Metoprolol succinate, Bisoprolol), Spironolactone, and ARNIs (Sacubitril/Valsartan). * **Digoxin:** Improves symptoms and reduces hospitalization but does **not** reduce mortality in CCF. * **Trimetazidine Side Effect:** Can cause or worsen **Parkinsonian symptoms** (tremors, rigidity) due to its effect on the nigrostriatal pathway.

Q: A patient developed acute congestive heart failure and was put on digitalis therapy. ECG of this patient revealed the presence of ventricular extrasystoles. Which of the following drugs can be administered safely to this patient in order to counteract this arrhythmia?

Lignocaine. **Explanation:** Digitalis (Digoxin) toxicity commonly manifests as cardiac arrhythmias, with **ventricular extrasystoles** (premature ventricular contractions) being one of the earliest and most frequent signs. This occurs due to increased intracellular calcium leading to delayed after-depolarizations (DADs). **Why Lignocaine is the Correct Choice:** Lignocaine (Lidocaine) is a **Class IB anti-arrhythmic** drug and is the drug of choice for digitalis-induced ventricular arrhythmias. It works by blocking activated and inactivated sodium channels, effectively suppressing ventricular ectopic foci without significantly depressing AV conduction or myocardial contractility. It has a high degree of safety in the setting of digitalis toxicity. **Why Other Options are Incorrect:** * **Quinidine (Option B):** It is strictly contraindicated. Quinidine reduces the renal and biliary clearance of Digoxin and displaces it from tissue binding sites, leading to a dangerous rise (doubling) in plasma Digoxin levels, worsening the toxicity. * **Atropine (Option C):** While Atropine is used to treat digitalis-induced bradycardia or AV block, it has no role in managing ventricular extrasystoles. * **Amiodarone (Option D):** Like Quinidine, Amiodarone can increase Digoxin levels by interfering with its excretion and is generally avoided in acute digitalis-induced ventricular arrhythmias. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Digitalis Toxicity:** Digoxin-specific Fab fragments (Digibind) is the definitive antidote. * **Electrolyte Imbalance:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose a patient to digitalis toxicity. * **ECG Sign of Toxicity:** Bigeminy (ventricular extrasystoles occurring every second beat) is a classic sign. * **ECG Sign of Digitalis Effect (Not Toxicity):** "Hockey stick" appearance or sagging ST-segment depression.

Q: Which drug is a potassium channel opener with anti-anginal activity?

Nicorandil. **Explanation:** **Nicorandil (Option A)** is the correct answer because it possesses a unique dual mechanism of action. It acts as a **Potassium channel opener** (specifically ATP-sensitive $K^+$ channels) and a **Nitrate-like vasodilator**. By opening $K^+$ channels in vascular smooth muscle, it causes hyperpolarization, leading to arterial vasodilation (reducing afterload). Its nitrate moiety increases cGMP, causing venous vasodilation (reducing preload). This dual action improves coronary blood flow and reduces myocardial oxygen demand, making it effective in stable angina. **Incorrect Options:** * **Dipyridamole (Option B):** This is a phosphodiesterase inhibitor and adenosine uptake inhibitor. While it is a vasodilator, it is notorious for causing **"Coronary Steal Phenomenon"** and is primarily used in pharmacological stress testing or as an antiplatelet agent. * **Dofetilide (Option C):** This is a **Class III Antiarrhythmic** drug. It acts by *blocking* potassium channels (specifically the $I_{Kr}$ current) to prolong the action potential duration, rather than opening them. * **Amiodarone (Option D):** A broad-spectrum Class III Antiarrhythmic that blocks $K^+$, $Na^+$, and $Ca^{2+}$ channels, and has anti-adrenergic effects. Like Dofetilide, it is a $K^+$ channel **blocker**. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effect:** A highly specific side effect of Nicorandil is **painful mucosal ulcerations** (oral, anal, or GI ulcers). * **Preconditioning:** Nicorandil mimics "ischemic preconditioning," providing a cardioprotective effect during episodes of ischemia. * **Contraindication:** Avoid use with PDE-5 inhibitors (e.g., Sildenafil) due to the risk of severe hypotension.

Question 1

Dopamine given in acute CHF does NOT act on which of the following receptors?

Accepted Answer

Alpha 1 receptors

Answer

Receptors present on renal blood vessels

Answer

D1 receptors

Answer

Beta 1 receptors

Question 2

Which of the following drugs is NOT used in the management of pulmonary hypertension?

Accepted Answer

Alpha blocker

Answer

Calcium channel blocker

Answer

Endothelin receptor antagonist

Answer

Prostacyclin

Question 3

All of the following antihypertensive drugs increase plasma renin activity except?

Accepted Answer

Clonidine

Answer

Hydralazine

Answer

Nifedipine

Answer

Captopril

Question 4

All of the following drugs are used in the management of acute myocardial infarction except?

Accepted Answer

Calcium channel blockers

Answer

Tissue plasminogen activator

Answer

Intravenous beta blockers

Answer

Acetylsalicylic acid

Question 5

All of the following are true regarding rabeprazole except:

Accepted Answer

It causes hypotension.

Answer

It is recommended as first-line treatment for angina.

Answer

It improves glycemic control.

Answer

It is not indicated for acute attack of angina.

Question 6

All of the following ACE inhibitors are prodrugs and are activated by esterases in the liver except?

Accepted Answer

Captopril

Answer

Ramipril

Answer

Perindopril

Answer

Spirapril

Question 7

Lignocaine is useful for the treatment of which of the following conditions?

Accepted Answer

Digitalis-induced ventricular extrasystoles

Answer

Atrial fibrillation

Answer

Paroxysmal supraventricular tachycardia

Answer

All of the above

Question 8

In congestive cardiac failure, which of the following is NOT used?

Accepted Answer

Trimetazidine

Answer

Spironolactone

Answer

Nitrates

Answer

Nesiritide

Question 9

A patient developed acute congestive heart failure and was put on digitalis therapy. ECG of this patient revealed the presence of ventricular extrasystoles. Which of the following drugs can be administered safely to this patient in order to counteract this arrhythmia?

Accepted Answer

Lignocaine

Answer

Quinidine

Answer

Atropine

Answer

Amiodarone

Question 10

Which drug is a potassium channel opener with anti-anginal activity?

Accepted Answer

Nicorandil

Answer

Dipyridamole

Answer

Dofetilide

Answer

Amiodarone

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?